168 related articles for article (PubMed ID: 33605429)
21. Minimal Residual Disease in Acute Myeloid Leukemia.
Gomez-Arteaga A; Guzman ML
Adv Exp Med Biol; 2018; 1100():111-125. PubMed ID: 30411263
[TBL] [Abstract][Full Text] [Related]
22. The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia.
Al-Mawali A; Gillis D; Lewis I
Am J Clin Pathol; 2009 Jan; 131(1):16-26. PubMed ID: 19095561
[TBL] [Abstract][Full Text] [Related]
23. Minimal residual disease detection by flow cytometry.
Ludwig WD
Lab Hematol; 2004; 10(3):169. PubMed ID: 15529435
[No Abstract] [Full Text] [Related]
24. Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia.
Oran B; Jorgensen JL; Marin D; Wang S; Ahmed S; Alousi AM; Andersson BS; Bashir Q; Bassett R; Lyons G; Chen J; Rezvani K; Popat U; Kebriaei P; Patel K; Rondon G; Shpall EJ; Champlin RE
Haematologica; 2017 Jan; 102(1):110-117. PubMed ID: 27540139
[TBL] [Abstract][Full Text] [Related]
25. Leukemia-associated aberrant immunophenotype in patients with acute myeloid leukemia: changes at refractory disease or first relapse and clinicopathological findings.
Cui W; Zhang D; Cunningham MT; Tilzer L
Int J Lab Hematol; 2014 Dec; 36(6):636-49. PubMed ID: 24602197
[TBL] [Abstract][Full Text] [Related]
26. Flow cytometry for minimal residual disease testing in acute leukemia: opportunities and challenges.
Gaipa G; Buracchi C; Biondi A
Expert Rev Mol Diagn; 2018 Sep; 18(9):775-787. PubMed ID: 30047795
[TBL] [Abstract][Full Text] [Related]
27. Using minimal (measurable) residual disease assessments to guide decision-making for timing of allogeneic transplantation in acute myeloid leukemia.
Fasan O
Curr Opin Hematol; 2019 Nov; 26(6):413-420. PubMed ID: 31503019
[TBL] [Abstract][Full Text] [Related]
28. Minimal Residual Disease in Acute Myeloid Leukemia.
Sung PJ; Luger SM
Curr Treat Options Oncol; 2017 Jan; 18(1):1. PubMed ID: 28110381
[TBL] [Abstract][Full Text] [Related]
29. [Measurement of minimal residual disease and its implication].
Tsurusawa M; Hori T
Nihon Rinsho; 2012 Apr; 70 Suppl 2():731-6. PubMed ID: 23134035
[No Abstract] [Full Text] [Related]
30. Residual disease by flow cytometry in patients with nucleophosmin-mutated acute myeloblastic leukemia.
Gao M; Zhao X
Ann Hematol; 2020 Nov; 99(11):2703-2704. PubMed ID: 32307567
[No Abstract] [Full Text] [Related]
31. [Quantification of minimal residual disease by multiparameter flow cytometry in acute myeloid leukemia. From diagnosis to prognosis].
Kern W; Haferlach T
Med Klin (Munich); 2005 Jan; 100(1):54-9. PubMed ID: 15654545
[TBL] [Abstract][Full Text] [Related]
32. Newly diagnosed adult AML and MPAL patients frequently show clonal residual hematopoiesis.
Fernandez C; Santos-Silva MC; López A; Matarraz S; Jara-Acevedo M; Ciudad J; Gutierrez ML; Sánchez ML; Salvador-Osuna C; Berruezo MJ; Díaz-Arias JÁ; Palomo-Hernández AM; Colado E; González N; Gallardo D; Asensio A; García-Sánchez R; Saldaña R; Cerveró C; Carboné-Bañeres A; Gutierrez O; Orfao A
Leukemia; 2013 Nov; 27(11):2149-56. PubMed ID: 23579575
[TBL] [Abstract][Full Text] [Related]
33. Residual disease by flow cytometry in patients with nucleophosmin-mutated acute myeloblastic leukemia.
Sorigue M; Espasa A; Zamora L; Junca J
Ann Hematol; 2020 May; 99(5):1135-1136. PubMed ID: 32170360
[No Abstract] [Full Text] [Related]
34. Integrating post induction WT1 quantification and flow-cytometry results improves minimal residual disease stratification in acute myeloid leukemia.
Marani C; Clavio M; Grasso R; Colombo N; Guolo F; Kunkl A; Ballerini F; Giannoni L; Ghiggi C; Fugazza G; Ravetti JL; Gobbi M; Miglino M
Leuk Res; 2013 Dec; 37(12):1606-11. PubMed ID: 23891447
[TBL] [Abstract][Full Text] [Related]
35. Stability of leukemia-associated aberrant immunophenotypes in patients with acute myeloid leukemia between diagnosis and relapse: comparison with cytomorphologic, cytogenetic, and molecular genetic findings.
Voskova D; Schoch C; Schnittger S; Hiddemann W; Haferlach T; Kern W
Cytometry B Clin Cytom; 2004 Nov; 62(1):25-38. PubMed ID: 15468339
[TBL] [Abstract][Full Text] [Related]
36. Measurement of Residual Disease in Acute Myeloid Leukemia.
Vedula RS; Lindsley RC
Curr Hematol Malig Rep; 2017 Dec; 12(6):574-581. PubMed ID: 29064024
[TBL] [Abstract][Full Text] [Related]
37. Patient-tailored analysis of minimal residual disease in acute myeloid leukemia using next-generation sequencing.
Malmberg EB; Ståhlman S; Rehammar A; Samuelsson T; Alm SJ; Kristiansson E; Abrahamsson J; Garelius H; Pettersson L; Ehinger M; Palmqvist L; Fogelstrand L
Eur J Haematol; 2017 Jan; 98(1):26-37. PubMed ID: 27197529
[TBL] [Abstract][Full Text] [Related]
38. Relevance of leukemic stem cells in acute myeloid leukemia: heterogeneity and influence on disease monitoring, prognosis and treatment design.
Wouters R; Cucchi D; Kaspers GJ; Schuurhuis GJ; Cloos J
Expert Rev Hematol; 2014 Dec; 7(6):791-805. PubMed ID: 25242511
[TBL] [Abstract][Full Text] [Related]
39. Automated analysis of acute myeloid leukemia minimal residual disease using a support vector machine.
Ni W; Hu B; Zheng C; Tong Y; Wang L; Li QQ; Tong X; Han Y
Oncotarget; 2016 Nov; 7(44):71915-71921. PubMed ID: 27713120
[TBL] [Abstract][Full Text] [Related]
40. Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia.
Ravandi F; Jorgensen J; Borthakur G; Jabbour E; Kadia T; Pierce S; Brandt M; Wang S; Konoplev S; Wang X; Huang X; Daver N; DiNardo C; Andreeff M; Konopleva M; Estrov Z; Garcia-Manero G; Cortes J; Kantarjian H
Cancer; 2017 Feb; 123(3):426-435. PubMed ID: 27657543
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
